Zydus Lifesciences Limited

ZYDUSLIFE

INE010B01027

Pharmaceuticals

Market Closed - NSE India S.E. Other stock markets 06:49:12 2025-12-10 am EST			5-day change	1st Jan Change
923.60 ^INR	+0.36%		-1.21%	-4.95%

Dec. 10	Indian Equities Extend Losses as Investors Turn Cautious Ahead of US Rate Decision	MT
Dec. 10	Zydus Lifesciences Launches Denosumab Biosimilar	MT

Zydus Lifesciences Limited Reports Earnings Results for the Fourth Quarter Ended March 31, 2025

Published on 05/20/2025 at 05:35 am EDT - Modified on 05/20/2025 at 06:35 am EDT

S&P Capital IQ

Zydus Lifesciences Limited

+0.36%

Zydus Lifesciences Limited reported earnings results for the fourth quarter ended March 31, 2025. For the fourth quarter, the company reported revenue was INR 66,085 million compared to INR 56,902 million a year ago. Net income was INR 11,709 million compared to INR 11,823 million a year ago.

Basic earnings per share from continuing operations was INR 11.64 compared to INR 11.66 a year ago. Diluted earnings per share from continuing operations was INR 11.64 compared to INR 11.66 a year ago. Basic earnings per share was INR 11.64 compared to INR 11.69 a year ago.

Diluted earnings per share was INR 11.64 compared to INR 11.69 a year ago.

Latest news about Zydus Lifesciences Limited

Dec. 10	Indian Equities Extend Losses as Investors Turn Cautious Ahead of US Rate Decision	MT
Dec. 10	Zydus Lifesciences Launches Denosumab Biosimilar	MT
Dec. 09	Zydus Lifesciences launches biosimilar denosumab 120 mg SC	RE
Dec. 09	Formycon, Zydus Sign Exclusive Deal for Keytruda Biosimilar in US, Canada	MT
Dec. 09	Formycon Secures Additional Commercialization Partnership for Keytruda Biosimilar	DP
Dec. 09	Formycon and Zydus partner for exclusive licensing and supply agreement of FYB206	RE
Dec. 04	Zydus Lifesciences Gets US FDA's Establishment Inspection Report for Jarod, India Unit	MT
Dec. 04	Zydus Lifesciences receives EIR for injectable facility located at Jarod	RE
Nov. 27	Zydus Lifesciences receives tentative approval from USFDA for empagliflozin and linagliptin tablets	RE
Nov. 27	Zydus Lifesciences Limited Receives Tentative Approval from USFDA for Empagliflozin and Linagliptin Tablets, 10 mg/5 mg and 25 mg/5 mg	CI
Nov. 26	Zydus and RK Pharma Enter into an Exclusive Licensing and Commercialization Agreement for a Novel 505(B)(2) Product of Supportive Oncology Treatment for the USA Market	CI
Nov. 26	Indian Equities Jump on Wednesday on Short Covering, Rate-Cut Optimism	MT
Nov. 26	Zydus Signs Exclusive Licensing Deal with US-based RK Pharma for Supportive Oncology Treatment Drug	MT
Nov. 26	Zydus Lifesciences and RK Pharma enter into exclusive licensing and commercialization agreement	RE
Nov. 25	Indian benchmark shares open higher on Fed rate cut optimism	RE
Nov. 25	Zydus Lifesciences Gets USFDA Nod for Verapamil ER Tablets	MT
Nov. 25	Zydus Lifesciences receives final approval from USFDA for Verapamil Hydrochloride extended-release tablets	RE
Nov. 25	Zydus Lifesciences Limited Receives Final Approval from United States Food and Drug Administration for Verapamil Hydrochloride Extended-Release Tablets USP, 120 mg, 180 mg and 240 mg	CI
Nov. 14	Zydus Lifesciences leuprolide acetate to be manufactured at SEZ1, Ahmedabad	RE
Nov. 14	Zydus Lifesciences receives final approval from US FDA for Leuprolide Acetate Injection	RE
Nov. 14	Zydus Lifesciences Limited Receives Final Approval from Usfda for Leuprolide Acetate Injection, 14 Mg/2.8Ml (1 Mg/0.2 Ml) Multiple-Dose Vial	CI
Nov. 13	Zydus Lifesciences - Closure of USFDA inspection at Zydus' oncology injectable manufacturing facility in Sez1, Ahmedabad	RE
Nov. 13	Zydus Lifesciences Limited Announces Closure of USFDA Inspection at Zydus' Oncology Injectable Manufacturing Facility in SEZ1, Ahmedabad	CI
Nov. 13	Zydus Lifesciences gets final approval from USFDA for diroximel fumarate delayed-release capsules	RE
Nov. 13	Zydus Lifesciences Limited Receives Final Approval from USFDA for Diroximel Fumarate Delayed-Release Capsules, 231 mg	CI

Chart Zydus Lifesciences Limited

Duration

Period

ZYDUSLIFE: Dynamic Chart

Company Profile

Zydus Lifesciences Limited is an India-based global life sciences company that discovers, develops, manufactures and markets a broad range of healthcare therapies. The Company is engaged in the business of integrated pharmaceutical operations. Its product portfolio includes active pharmaceutical ingredients (API), human formulations, animal health and veterinary, health, and wellness products. Its products include India formulations, Generics and Zydus biologics. The Company's products include Lipaglyn and Bilypsa (Saroglitazar), Ujvira (Trastuzumab emtansine biosimilar), Exemptia (Adalimumab biosimilar), Vivitra (Trastuzumab biosimilar) and Bryxta (Bevacizumab biosimilar). Its Zydus biologics covers various therapeutic areas, such as oncology, autoimmune disease, nephrology, inflammation, rheumatology, hepatology and infectious illnesses, among others. The Company has a global presence and markets its products in the United States, India, Europe and emerging markets.

Employees

27,917

Sector

Pharmaceuticals

Calendar

Feb. 04 - Q3 2026 Earnings Release (Projected)

More about the company